PDF(Pubmed)
Abstract：
Introduction: The unmet need for highly effective, naturally derived products with minimal side effects results in the over-popularity of ever-newer medicinal plants. In the middle of 2010, products containing cannabidiol (CBD), one of the special metabolites of Cannabis sativa, started to gain popularity. For consumers and healthcare providers alike, the legal context surrounding the marketing of CBD products is not entirely clear, and the safety of using some products is in doubt. Companies in the online medicinal product market profit from the confusion around CBD oils. Methods: In our study, we employed a complex method known as risk-based safety mapping of the online pharmaceutical market, which included health claim content analysis of online stores, test purchases, and labeling and quantitative analysis of the CBD content. Results: There were discovered 16 online retailers selling an average of 2-7 goods and CBD oils with a concentration of 3%-5% (30-50 mg/mL) CBD. The majority (n/N = 10/16, 62.5%) displayed potential health-related benefits indirectly on their website, and in the case of one web shop (n/N = 1/16, 6.3%), we detected COVID-19-related use. Altogether, 30 types of purported \"indications\" were collected. A total of 12 CBD oil products were test-purchased from online retailers in December 2020. Upon evaluating the packaging and product information, we noticed that three products (n/N = 3/12, 25%) lacked instructions on use, hence increasing the risk of inappropriate application and dosing. The cannabidiol content was quantified using UHPLC. The measured CBD concentrations of the products ranged from 19.58 mg/mL to 54.09 mg/mL (mean 35.51 mg/mL, median 30.63 mg/mL, and SD ± 12.57 mg/mL). One (8.33%) product was underlabeled, five (41.67%) were over-labeled, and only every second product (50%) was appropriately labeled based on the quantitative assessment of CBD concentration. Discussion: Further research and quality control are necessary to establish the regulatory context of the usage and classification of CBD and other cannabinoids in nonmedicinal products (e.g., food supplements), as authorities and policymakers worldwide struggle with the uncertainties surrounding CBD products.
摘要：
导言:对高效的未满足需求，具有最小副作用的天然衍生产品导致更新的药用植物过度流行。在2010年中期，含有大麻二酚（CBD）的产品，大麻的一种特殊代谢产物,开始受欢迎。对于消费者和医疗保健提供者来说，围绕CBD产品营销的法律背景并不完全清楚，使用某些产品的安全性令人怀疑。在线医药产品市场的公司从CBD油的混乱中获利。方法：在我们的研究中，我们采用了一种复杂的方法，称为基于风险的在线药品市场安全映射，其中包括在线商店的健康声明内容分析，测试购买，以及CBD含量的标记和定量分析。结果：发现有16家在线零售商平均销售2-7种商品和CBD油，其浓度为3％-5％（30-50mg/mL）CBD。大多数（n/N=10/16，62.5%）在其网站上间接显示了潜在的健康相关益处，如果是一家网店(n/N=1/16，6.3%)，我们检测到与COVID-19相关的使用。总之,收集了30种所谓的“适应症”。2020年12月，共有12种CBD石油产品从在线零售商处进行了测试购买。在评估包装和产品信息时，我们注意到三种产品(n/N=3/12，25%)缺乏使用说明，因此增加了不适当的应用和剂量的风险。使用UHPLC定量大麻二酚含量。测得的产品的CBD浓度范围为19.58mg/mL至54.09mg/mL（平均35.51mg/mL，中位数30.63mg/mL，和SD±12.57mg/mL）。一个(8.33%)产品标签不足,5人(41.67%)被过度标记，并且根据CBD浓度的定量评估，仅每隔一个产品（50％）被适当标记。讨论：需要进一步的研究和质量控制，以建立非药用产品中CBD和其他大麻素的使用和分类的监管背景（例如，食品补充剂)，世界各地的当局和政策制定者都在与CBD产品周围的不确定性作斗争。
